candesartan cilexetil has been researched along with Neointima in 1 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Neointima: The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichikawa, N | 1 |
| Toma, N | 1 |
| Kawakita, F | 1 |
| Matsushima, S | 1 |
| Imanaka-Yoshida, K | 1 |
| Yoshida, T | 1 |
| Taki, W | 1 |
| Suzuki, HI | 1 |
1 other study available for candesartan cilexetil and Neointima
| Article | Year |
|---|---|
Angiotensin II type 1 receptor blockers suppress neointimal hyperplasia after stent implantation in carotid arteries of hypercholesterolemic rabbits.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Carotid Artery | 2015 |